Many platforms used by investigators were never designed with clinical trials in mind. The consequence is a widening infrastructure gap that leaves independent investigators operating complicated ...
In today's ACT Brief, we examine the technology infrastructure gap facing investigator-initiated trials, how transparency and community engagement drive vaccine adoption, and why workflow ...
Vaccine hesitancy is widely recognized as one of the most significant public health problems of the 21 st Century. The World Health Organization (WHO) identifies vaccine hesitancy ...
In this video interview, Marc Buyse, ScD, founder and CEO of IDDI, makes the case for generalized pairwise comparisons and the win ratio as transformative approaches to trial analysis that incorporate ...
In this video interview, David Morton, PhD, director of biostatistics at Certara, reflects on the growing role of Bayesian ...
Senior Director, IQVIA Participant Payments, at IQVIA. Prior to this, Mr. Williams was Vice President, Investigator Management Solutions at Syneos Heal ...
Associate Director of Participant Payments at IQVIA with extensive experience supporting global clinical trials. In this role, Taylor oversees participant payment strategy and execution across diverse ...
In today’s ACT Brief, we highlight how Bayesian methods are reshaping adaptive trial design, a major eSource partnership is ...
That's the purpose of the estimand framework—to define ahead of time, before you even start randomizing patients, everything that can happen, and then define the methods you will use to attenuate the ...
Closing the gender gap in data science and tech requires tackling barriers at every stage, from early education through career advancement, while actively challenging the unconscious biases that ...
In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...
An in-depth thought leadership whitepaper explaining how sponsors can operationalize the FDA’s 2025 guidance on inclusive and representative clinical trial design. It outlines current industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results